Effects of chemotherapeutic agents and immunomodulators on host defense mechanisms: a basis for less empirical chemoimmunotherapy approaches

A. Mantovani, A. Tagliabue, A. Vecchi

Research output: Contribution to journalArticle

Abstract

The effect of antineoplastic agents on immune responses is heterogenous. Moreover, the immunomodulators usually employed in experimental and clinical studies seem to act differentially on humoral and cellular immune functions and on the cell-subpopulations involved in these functions. Thus, taking into account the different activities of immunodepressive and immunostimulant agents, a rationale can be developed in drawing experimental immunotherapeutic protocols. The results obtained combining several antineoplastic drugs (Adriamycin, Cyclophosphamide, 5-Fluorouracil, Daunomycin) and several immunomodulators (Corynebacterium parvum, BCG and Levamisole) are summarized. The experimental data show that the best therapeutic activity can be achieved with those combinations (Adriamycin - C. parvum and Cyclophosphamide C. parvum) that were expected to give a synergistic effect from the basic data previously obtained.

Original languageEnglish
Pages (from-to)83-92
Number of pages10
JournalChemioterapia Oncologica
Volume4
Issue number2
Publication statusPublished - 1980

Fingerprint

Propionibacterium acnes
Immunologic Factors
Antineoplastic Agents
Doxorubicin
Cyclophosphamide
Immunologic Adjuvants
Levamisole
Daunorubicin
Mycobacterium bovis
Fluorouracil
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{50699b76605e439388369b6d10a0073e,
title = "Effects of chemotherapeutic agents and immunomodulators on host defense mechanisms: a basis for less empirical chemoimmunotherapy approaches",
abstract = "The effect of antineoplastic agents on immune responses is heterogenous. Moreover, the immunomodulators usually employed in experimental and clinical studies seem to act differentially on humoral and cellular immune functions and on the cell-subpopulations involved in these functions. Thus, taking into account the different activities of immunodepressive and immunostimulant agents, a rationale can be developed in drawing experimental immunotherapeutic protocols. The results obtained combining several antineoplastic drugs (Adriamycin, Cyclophosphamide, 5-Fluorouracil, Daunomycin) and several immunomodulators (Corynebacterium parvum, BCG and Levamisole) are summarized. The experimental data show that the best therapeutic activity can be achieved with those combinations (Adriamycin - C. parvum and Cyclophosphamide C. parvum) that were expected to give a synergistic effect from the basic data previously obtained.",
author = "A. Mantovani and A. Tagliabue and A. Vecchi",
year = "1980",
language = "English",
volume = "4",
pages = "83--92",
journal = "Chemioterapia Oncologica",
issn = "0392-0968",
number = "2",

}

TY - JOUR

T1 - Effects of chemotherapeutic agents and immunomodulators on host defense mechanisms

T2 - a basis for less empirical chemoimmunotherapy approaches

AU - Mantovani, A.

AU - Tagliabue, A.

AU - Vecchi, A.

PY - 1980

Y1 - 1980

N2 - The effect of antineoplastic agents on immune responses is heterogenous. Moreover, the immunomodulators usually employed in experimental and clinical studies seem to act differentially on humoral and cellular immune functions and on the cell-subpopulations involved in these functions. Thus, taking into account the different activities of immunodepressive and immunostimulant agents, a rationale can be developed in drawing experimental immunotherapeutic protocols. The results obtained combining several antineoplastic drugs (Adriamycin, Cyclophosphamide, 5-Fluorouracil, Daunomycin) and several immunomodulators (Corynebacterium parvum, BCG and Levamisole) are summarized. The experimental data show that the best therapeutic activity can be achieved with those combinations (Adriamycin - C. parvum and Cyclophosphamide C. parvum) that were expected to give a synergistic effect from the basic data previously obtained.

AB - The effect of antineoplastic agents on immune responses is heterogenous. Moreover, the immunomodulators usually employed in experimental and clinical studies seem to act differentially on humoral and cellular immune functions and on the cell-subpopulations involved in these functions. Thus, taking into account the different activities of immunodepressive and immunostimulant agents, a rationale can be developed in drawing experimental immunotherapeutic protocols. The results obtained combining several antineoplastic drugs (Adriamycin, Cyclophosphamide, 5-Fluorouracil, Daunomycin) and several immunomodulators (Corynebacterium parvum, BCG and Levamisole) are summarized. The experimental data show that the best therapeutic activity can be achieved with those combinations (Adriamycin - C. parvum and Cyclophosphamide C. parvum) that were expected to give a synergistic effect from the basic data previously obtained.

UR - http://www.scopus.com/inward/record.url?scp=0019258374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019258374&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0019258374

VL - 4

SP - 83

EP - 92

JO - Chemioterapia Oncologica

JF - Chemioterapia Oncologica

SN - 0392-0968

IS - 2

ER -